CRL — Charles River Laboratories International, Inc.

Summary of Charles River Laboratories Q2 2026 Earnings Call

1. Key Financial Results and Metrics:

• Revenue: Increased 0.1% organically, contrary to prior expectations of a low single-digit decline.
• Non-GAAP Earnings Per Share (EPS): Rose to $3.02, a 47% sequential increase, exceeding the forecast of at least 30% growth.
• Operating Margin: Improved by 420 basis points sequentially to 20.5%, attributed to divestitures and reduced margin pressures from the previous quarter.
• Net Book-to-Bill Ratio: Reached 1.19x, with net bookings of $701 million, marking the highest level in nearly four years.
• Free Cash Flow: Reported at $149 million, a decrease from the previous year, but full-year guidance raised to $400 million to $420 million.

2. Strategic Updates and Business Highlights:

• Pathway to Purpose Strategy: Focused on modernizing the company, enhancing scientific portfolios, and improving client-centric approaches.
• Collaborations: Announced partnerships with Eli Lilly and Arovella Therapeutics to enhance drug discovery and cancer treatment capabilities.
• Divestitures: Completed divestitures of certain European discovery services and CDMO businesses, contributing to operating margin improvements.
• Laboratory Expansion: Ongoing expansions in bioanalytical laboratory capacity to support growing demand in lab sciences.

3. Forward Guidance and Outlook:

• 2026 Financial Guidance: Revenue expected to decline 2.5% to 3.5% (reported) but organic growth raised to flat to 1% increase. DSA revenue outlook adjusted to low single-digit growth.
• Operating Margin Expansion: Anticipated improvement of 120 to 150 basis points for the year, with significant contributions from the Manufacturing and DSA segments.
• Q3 Expectations: Revenue projected to decline 4% to 6% (reported) but organic growth of 1% to 3% anticipated, with a sequential operating margin improvement of approximately 200 basis points.

4. Bad News, Challenges, or Points of Concern:

• RMS Segment Decline: Organic revenue decreased 1.4%, primarily due to lower demand from academic and government clients, with expectations for continued low to mid-single-digit declines in 2026.
• Tax Rate Increase: Non-GAAP tax rate projected to rise to 23% to 24%, presenting a $0.20 headwind to EPS.
• Market Pressures: Competitive pressures from Chinese CROs and potential in-sourcing by large pharma clients could impact future growth.

5. Notable Q&A Insights:

• AI and Drug Discovery: Management expressed optimism about AI's role in enhancing drug discovery efficiency, though the timeline for significant impacts remains uncertain.
• Capacity and Utilization: Current capacity is sufficient to meet demand, but ongoing expansions are necessary to support future growth.
• NHP Supply: Control over NHP supply through recent acquisitions is seen as a competitive advantage, with expectations for improved margins in Q4 due to lower sourcing costs.
• Demand Trends: Both small and midsized biotech and global biopharma clients are showing improved demand, but the timing of bookings converting to revenue remains a challenge.

This summary encapsulates the key points from the earnings call, providing a balanced view of the company's performance, strategic direction, and market challenges.